Iterum Therapeutics Faces Commercialization Challenges for ORLYNVAH™ Despite FDA Approval

Iterum Therapeutics (ITRM) has disclosed a new risk, in the Sales & Marketing category.

Iterum Therapeutics faces a significant business risk as it lacks established sales, marketing, and distribution capabilities, which may hinder the successful commercialization of ORLYNVAH™ and sulopenem in additional indications. Despite receiving FDA approval for ORLYNVAH™ and engaging a financial advisor to explore strategic alternatives, the company remains without the necessary infrastructure or experience to directly market their products. If they fail to develop these capabilities or secure favorable third-party arrangements, their operating results could suffer due to delays or increased costs. The company’s ability to maximize shareholder value depends on effectively navigating these challenges and potentially collaborating with partners who possess relevant commercialization expertise.

Overall, Wall Street has a Moderate Buy consensus rating on ITRM stock based on 1 Buy.

To learn more about Iterum Therapeutics’ risk factors, click here.